<i style="mso-bidi-font-style:normal">Leishmania donovani</i> secretory serine protease alters macrophage inflammatory response via COX-2 mediated PGE-2 production

Abstract

<i style="mso-bidi-font-style:normal">Leishmania</i> parasites determine the outcome of the infection by inducing inflammatory response that suppresses macrophage’s activation<b style="mso-bidi-font-weight:normal">. </b>Defense against <i style="mso-bidi-font-style: normal">Leishmania</i> is dependent on Th1 inflammatory response by turning off macrophages’ microbicidal property by upregulation of COX-2, as well as immunosuppressive PGE-2 production.<b style="mso-bidi-font-weight:normal"> </b>To understand the role of <i style="mso-bidi-font-style:normal">L. donovani</i> secretory serine protease (pSP) in these phenomena, pSP was inhibited by its antibody and serine protease inhibitor, aprotinin. Western blot and TAME assay demonstrated that pSP antibody and aprotinin significantly inhibited protease activity in the live <i style="mso-bidi-font-style:normal">Leishmania</i> cells and reduced infection index of <i style="mso-bidi-font-style:normal">L. donovani</i>-infected macrophages. Additionally, ELISA and RT-PCR analysis showed that treatment with pSP antibody or aprotinin hold back COX-2-mediated immunosuppressive PGE-2 secretion with enhancement of Th1 cytokine like IL-12 expression. This was also supported in Griess test and NBT assay, where inhibition of pSP with its inhibitors elevated ROS and NO production. Overall, our study implies the pSP is involved in down-regulation of macrophage microbicidal activity by inducing host inflammatory responses in terms of COX-2-mediated PGE-2 release with diminished reactive oxygen species generation and thus suggests its importance as a novel drug target of visceral leishmaniasis.